US Patent 10,301,393: What do the CD20 IgG variable-sequence claims really cover?
US 10,301,393 claims methods of treating multiple sclerosis (MS) by administering a CD20-specific immunoglobulin whose VH and VL variable regions are defined by specific sequence identifiers, with narrower dependent claims that add an IgG1 kappa format and a CDC-over-rituximab property. The enforceable value hinges on (i) how narrowly those SEQ ID NO pairs anchor the scope and (ii) whether the patent is likely to face obviousness or anticipation from prior CD20 antibodies and MS rituximab-derivatives, including newer glycoengineering and CDC-enhanced variants.
What is the claim scope in technical terms?
Independent claim 1: CD20-binding Ig with defined VH/VL pairings
Claim 1 covers an MS treatment method by administering an effective amount of an immunoglobulin that:
- Specifically binds CD20
- Contains:
- a heavy chain variable (VH) domain and
- a light chain variable (VL) domain
- Uses one VH and one VL selected from a set of SEQ ID combinations:
- (a) VH = SEQ ID 12, VL = SEQ ID 10
- (b) VH = SEQ ID 13, VL = SEQ ID 10
- (c) VH = SEQ ID 14, VL = SEQ ID 10
- (d) VH = SEQ ID 15, VL = SEQ ID 10
- (e) VH = SEQ ID 16, VL = SEQ ID 10
- (f) VH = SEQ ID 17, VL = SEQ ID 10
- (g) VH = SEQ ID 18, VL = SEQ ID 10
- (h) VH = SEQ ID 13, VL = SEQ ID 11
- (i) VH = SEQ ID 16, VL = SEQ ID 11
Core legal effect: claim 1 is an “administration” claim with product-defined structural limits. It does not merely claim “any CD20 antibody that treats MS.” It requires a CD20 antibody whose variable-region sequences match at least one of the enumerated VH/VL pairings.
Dependent claims: incremental tightening
- Claim 2: VH = SEQ ID 16 and VL = SEQ ID 10
- Claim 3: immunoglobulin has increased CDC vs rituximab
- Claim 4: immunoglobulin is IgG1 kappa
- Claim 5: human constant regions:
- human IgG1 constant region in heavy chain
- human kappa constant region in light chain
- Claim 6: subject is human
Practical meaning: the independent claim can be infringed by any IgG format (unless excluded by the written description elsewhere in the patent), but enforcement pressure increases under dependent claims that lock in IgG1 kappa and human constant regions plus a functional CDC superiority condition.
How strong are the claim elements against obviousness/anticipation?
1) CD20 binding + MS treatment is broad in concept but narrow in implementation
In patent litigation, “treat MS with anti-CD20” is the kind of therapeutic concept that often has prior art coverage. The differentiator here is structural: specific VH/VL sequence pairs. If those sequences correspond to known/obvious CD20 clones, anticipation or obviousness becomes much more plausible.
2) The SEQ ID pairing requirement creates a hard technical gate
The list of allowed VH/VL combinations acts like a specificity filter. For infringement, a generic “CD20 antibody” design-around that uses a different VH or VL can avoid claim 1 unless it still falls inside one of the listed pairs.
For validity, however, sequence-specific claims are only strong if the enumerated sequences are not disclosed earlier (as exact sequences or as readily derivable equivalents). Without disclosure of the SEQ IDs in earlier publications or patents, anticipation weakens. With disclosure, the claim can collapse quickly.
3) Claim 3’s “increased CDC vs rituximab” is both valuable and risky
- Valuable because it adds a functional superiority requirement tied to complement-mediated cytotoxicity.
- Risky because CDC is sensitive to assay conditions, glycosylation, epitope angle, and Fc engineering.
- Legally, if prior art antibodies already show equal or higher CDC in relevant assays, claim 3 becomes vulnerable.
Also, if the patent does not provide robust comparative data tied to a clinically meaningful window, CDC superiority can be attacked as non-limiting or not commensurate with scope.
4) IgG1 kappa + human constant regions are format locks that may be already common
IgG1 kappa is a standard backbone. If the patent’s novelty depends mainly on backbone rather than the variable region, claim 4 and 5 may not provide meaningful incremental patentability.
What is the likely patent landscape around these claims?
The landscape anchor: rituximab and ofatumumab-like precedent
Historically, rituximab is a CD20 antibody used off-label (and later more formally in some contexts) for MS and other autoimmune diseases. Second-generation CD20 antibodies expanded options; some were designed for binding, CDC, or internalization profile differences.
Within this landscape, the question is not whether CD20 antibodies treat autoimmune disease; the question is whether the exact VH/VL variable sequences listed in US 10,301,393 were novel at filing, and whether they were obvious to obtain from known clones.
CDC-enhanced CD20 antibodies are common design targets
CDC performance frequently correlates with:
- Fc glycosylation state (e.g., fucosylation affects ADCC; sialylation and overall glycan structures can affect CDC in certain contexts)
- epitope and binding orientation to promote complement activation
- Ig subclass and Fc engineering choices
Because CDC is a known optimization axis, claim 3 can attract prior art CD20 variants with improved CDC relative to older comparators.
Sequence-defined antibodies: the landscape is fragmented but crowded
For sequence-defined antibody patents, enforceability often turns on whether earlier patents or publications:
- disclose the same VH and VL sequences,
- disclose the same complementarity-determining regions (CDRs) in a way that effectively enables the same sequences, or
- disclose near-identical variants that an examiner or challenger can argue are an obvious substitution.
Bottom line for landscape criticality: even if MS-specific administration was a known target, this patent’s survival odds depend on novelty of the specific VH and VL sequence pairs and the robustness of CDC superiority data for the claimed constructs.
Where are the enforceability pressure points?
A) Infringement hinges on matching SEQ ID pairs
Because claim 1 limits the VH/VL to enumerated sequence identifiers, a competitor’s antibody can avoid claim 1 if either:
- it uses a different VH sequence not listed for that VL, or
- it uses a different VL not listed for that VH.
This creates a narrow infringement window. From a business perspective, the patent is strongest when the market product planned uses these exact variable sequences.
B) Dependent claims may fail if the competitor changes format
Claim 4 requires IgG1 kappa. Claim 5 requires human IgG1 constant region and human kappa constant region. A competitor could evade those dependent claims by:
- moving to a different subclass (IgG2, IgG4) or
- using a different constant region set, or
- altering the light chain constant framework.
C) Claim 3 adds a functional condition that can be contested
Even if variable sequences match, CDC superiority can be challenged on:
- assay systems (serum source, rabbit or human complement, temperature, incubation times),
- target cell line selection,
- antibody concentration and exposure duration,
- whether the comparator “rituximab” matches the same formulation and handling.
Functional superiority conditions often become litigation bottlenecks.
What is the critical business interpretation of each claim?
Claim 1
- Breadth: medium-to-narrow due to enumerated VH/VL combinations.
- Commercial relevance: high if an MS CD20 antibody pipeline targets those exact variable sequences.
- Risk: validity depends on prior disclosure of those sequences (or their CDR equivalents) in earlier patents/publications.
Claim 2
- Breadth: very narrow (one VH/VL pair).
- Commercial relevance: strong for a single lead asset.
- Risk: if SEQ ID 16 (VH) and SEQ ID 10 (VL) are disclosed earlier, this claim is at direct anticipation risk.
Claim 3
- Breadth: constrained by a performance attribute rather than an explicit sequence feature.
- Commercial relevance: high because CDC enhancement is a differentiator.
- Risk: CDC is assay-sensitive; the legal robustness depends on strong comparative support.
Claim 4 and 5
- Breadth: narrow format constraints that may be common in the field.
- Commercial relevance: protects specific Fc/light framework selections.
- Risk: these elements may not confer meaningful novelty; they can be attacked as obvious design choices if variable regions are the real novelty.
Claim 6
- Breadth: human administration is standard for MS.
- Commercial relevance: mostly defensive; limited incremental patent value.
Key Takeaways
- US 10,301,393 is a CD20-MS method patent whose enforceable core is sequence-defined variable regions (VH/VL SEQ ID pairings), not general anti-CD20 utility.
- The patent’s competitive leverage is narrow: infringement likely requires matching at least one enumerated VH/VL combination and (for stronger claims) IgG1 kappa human constant frameworks plus (for claim 3) CDC superiority vs rituximab.
- Validity and litigation posture will likely turn on whether earlier art discloses the same (or effectively equivalent) variable sequences and whether CDC improvements were already known for comparable CD20 antibodies in commensurate experimental setups.
FAQs
1) What is the main novelty driver of US 10,301,393?
The variable-region limitation: claim 1 requires CD20 immunoglobulins whose VH and VL correspond to specific SEQ ID combinations rather than generic “CD20 binding.”
2) Can a company avoid claim 1 by using a different light chain?
Yes. Claim 1 only covers antibodies whose VH and VL match one of the enumerated SEQ ID pairings.
3) Does claim 3 cover all CDC-increasing CD20 antibodies?
No. Claim 3 is limited to the immunoglobulin of claim 1, then adds the condition that it has increased CDC versus rituximab.
4) Is IgG1 kappa likely a meaningful narrowing in a competitive landscape?
It narrows dependent claims, but IgG1 kappa is a common format, so the added limitation may not provide strong incremental novelty by itself.
5) Which claim is most commercially actionable for an asset already in development?
The actionable claim is the one whose VH/VL sequences match the program’s antibody. If the program uses the SEQ ID 16 (VH) and SEQ ID 10 (VL) pair, claim 2 aligns directly; if it also matches IgG1 kappa with human constant regions and shows CDC improvement, claims 3 to 5 stack.
References (APA)
[1] U.S. Patent No. 10,301,393. (n.d.). United States Patent and Trademark Office.
